PONSTAN DIN 00155225
Health Canada record
| Active ingredient(s) | MEFENAMIC ACID 250 MG |
|---|---|
| Dosage form | Capsule |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | M01AG01 MEFENAMIC ACID |
| Original market date | 31-Dec-1966 |
| Current status date | 31-Jul-2019 |
| Source | Health Canada DPD |
Establishment licence of the holder
AA Pharma Inc. — licence 101851, currently licensed, last inspection rating C (2023-05-23).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing MEFENAMIC ACID
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02229452 | MEFENAMIC | AA PHARMA INC | Capsule | MEFENAMIC ACID 250 MG | Marketed |
| 02229569 | MEFENAMIC ACID | APOTEX INC | Capsule | MEFENAMIC ACID 250 MG | Approved |
| 02237826 | DOM-MEFENAMIC ACID | DOMINION PHARMACAL | Capsule | MEFENAMIC ACID 250 MG | Cancelled Post Market |
| 02230408 | MEFENAMIC-250 | PRO DOC LIMITEE | Capsule | MEFENAMIC ACID 250 MG | Cancelled Post Market |
| 02239836 | NOVO-MEFENAMIC CAPSULES 250MG | NOVOPHARM LIMITED | Capsule | MEFENAMIC ACID 250 MG | Cancelled Pre Market |
| 02231208 | PMS-MEFENAMIC ACID | PHARMASCIENCE INC | Capsule | MEFENAMIC ACID 250 MG | Cancelled Post Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 19602 | 2017-07-27 | New Drug Submission (NDS) | TRANSFER OF DRUG IDENTIFICATION NUMBER |
| 18476 | 2016-09-13 | New Drug Submission (NDS) | TRANSFER OF DRUG IDENTIFICATION NUMBER |
| 7240 | 2005-07-12 | New Drug Submission (NDS) | MANUFACTURER NAME CHANGE |
| 2454 | 2001-01-18 | New Drug Submission (NDS) | MANUFACTURER NAME CHANGE |
International API supply for MEFENAMIC ACID
4 valid EDQM Certificates of Suitability from 4 holders. 8 active FDA Drug Master Files.
Request a quote for PONSTAN